CSL Behring announced today that Helixate® FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. FDA for routine prophylaxis in children with hemophilia A who are 16 years old or younger and do not have pre-existing joint damage.
The details can be read here.
No comments:
Post a Comment